• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments.确定恩沃利单抗和帕博利珠单抗用于转移性膀胱癌的适用性：是时候超越单纯的合并症评估了。
ESMO Open. 2024 Nov;9(11):103985. doi: 10.1016/j.esmoop.2024.103985. Epub 2024 Nov 13.
2
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
3
Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.恩扎妥昔单抗联合或不联合帕博利珠单抗治疗转移性尿路上皮癌：一项系统评价和荟萃分析。
JAMA Netw Open. 2025 Mar 3;8(3):e250250. doi: 10.1001/jamanetworkopen.2025.0250.
4
Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.在晚期尿路上皮癌患者中使用恩杂鲁胺+帕博利珠单抗治疗期间管理潜在不良事件。
Front Oncol. 2024 Apr 22;14:1326715. doi: 10.3389/fonc.2024.1326715. eCollection 2024.
5
Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report.恩杂鲁胺治疗后转移性膀胱癌形成乙状结肠直肠瘘：一例报告
Front Oncol. 2023 Nov 9;13:1274494. doi: 10.3389/fonc.2023.1274494. eCollection 2023.
6
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.恩扎妥昔单抗和帕博利珠单抗：重新定义既往未治疗的晚期尿路上皮癌的治疗标准。
Future Oncol. 2025 May;21(11):1333-1348. doi: 10.1080/14796694.2025.2482363. Epub 2025 Mar 25.
7
Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.免疫检查点抑制剂治疗后使用恩杂鲁胺维莫非尼及日本转移性尿路上皮癌的预后：转移性尿路上皮癌中恩杂鲁胺维莫非尼的大型数据库研究
Cancers (Basel). 2023 Aug 23;15(17):4227. doi: 10.3390/cancers15174227.
8
Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.在恩福妥单抗-维迪昔单抗时代前，接受派姆单抗治疗后进展的晚期尿路上皮癌患者的临床实践模式。
Int J Urol. 2022 Jul;29(7):647-655. doi: 10.1111/iju.14861. Epub 2022 Mar 18.
9
Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases.恩杂鲁胺与放疗联合治疗转移性尿路上皮癌后的持久反应：两例报告
Cureus. 2023 Dec 4;15(12):e49936. doi: 10.7759/cureus.49936. eCollection 2023 Dec.
10
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.探索一种新的治疗联合方案用于未经治疗的局部晚期或转移性尿路上皮癌：恩福妥单抗维迪妥珠单抗联合帕博利珠单抗。
Future Oncol. 2024 Mar;20(7):351-360. doi: 10.2217/fon-2023-0112. Epub 2023 Nov 23.

本文引用的文献

1
The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.恩杂鲁胺和帕博利珠单抗在晚期尿路上皮癌患者中的临床应用：基于治疗标准运用临床判断
ESMO Open. 2024 Sep;9(9):103725. doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.
2
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
3
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.治疗不适合顺铂为基础化疗的转移性尿路上皮癌患者。
J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9.
4
The need for a new medical model: a challenge for biomedicine.新医学模式的需求：对生物医学的挑战。
Science. 1977 Apr 8;196(4286):129-36. doi: 10.1126/science.847460.

Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments.

作者信息

Russell B M, Fein D E C, Bellmunt J

机构信息

Beth Israel Deaconess Medical Center, Boston, USA.

Beth Israel Deaconess Medical Center, Boston, USA.

出版信息

ESMO Open. 2024 Nov;9(11):103985. doi: 10.1016/j.esmoop.2024.103985. Epub 2024 Nov 13.

DOI:10.1016/j.esmoop.2024.103985
PMID:39541622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11613159/
Abstract
摘要